Avalo Therapeutics Will Sell Its AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics For An Upfront Payment Of $150K
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics is selling its AVTX-801, AVTX-802, and AVTX-803 to AUG Therapeutics for an upfront payment of $150,000. Additionally, AUG will make a contingent milestone payment of $15,000,000 for each compound if the first FDA approval is for an indication other than a Rare Pediatric Disease, potentially aggregating to $45 million. AUG will also pay up to 20% of certain payments if any priority review voucher is granted by the FDA and sold.
September 12, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avalo Therapeutics is selling three of its compounds to AUG Therapeutics, potentially leading to significant future revenue if FDA approvals are granted and priority review vouchers are sold.
The sale of these compounds could potentially bring in significant revenue for Avalo Therapeutics, especially if the FDA grants approvals for indications other than Rare Pediatric Disease and if priority review vouchers are sold. This could positively impact the company's financial performance and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100